Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HQ2216 injection to reduce rebleeding after endoscopic hemostasis for peptic ulcer bleeding
CTR20260898Phase 2Active
- Sponsor
- 百诚医药
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of esomeprazole sodium in Peptic ulcer disease (PUD), sponsored by 百诚医药. Started May 2026; status: active.
02
Drugs
esomeprazole sodium
03
Conditions
Peptic ulcer disease (PUD)
Beyond the preview
Go deeper on CTR20260898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260898.